Evidence map›Paper›PMID 35353227›Full record

ReviewHuman genetics2022

The genetic and phenotypic landscapes of Usher syndrome: from disease mechanisms to a new classification.

Sedigheh Delmaghani, Aziz El-Amraoui

Open access · hybridAbstract readReview
In one paragraph

Review in Human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 109 citations in OpenAlex.

  1. Review
  2. Review
  3. Association ofInternational journal of molecular sciences · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. From Sound to Stability: Lessons Learned From the CRUSH Study on Hearing Loss Progression and Vestibular Phenotype in Usher Syndrome Type 2A.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2026
    Observational
  10. Article
  11. Article
  12. Article
  13. AFrontiers in cell and developmental biology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. A Genomic Analysis of Usher Syndrome: Population-Scale Prevalence and Therapeutic Targets.American journal of medical genetics. Part C, Seminars in medical genetics · 2025
    Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sedigheh DelmaghaniInstitut Pasteur, Institut de l'Audition, Université Paris Cité, INSERM UMRS1120, Progressive Sensory Disorders, Pathophysiology and Therapy Unit, F-75012, Paris, France. sedigheh.delmaghani@pasteur.fr.ORCID http://orcid.org/0000-0003-2092-5097
Aziz El-AmraouiInstitut Pasteur, Institut de l'Audition, Université Paris Cité, INSERM UMRS1120, Progressive Sensory Disorders, Pathophysiology and Therapy Unit, F-75012, Paris, France. aziz.el-amraoui@pasteur.fr.ORCID http://orcid.org/0000-0003-2692-4984
Inserm · FR

Funding

Agence Nationale de la Recherche ANR-15-RHUS-0001Agence Nationale de la Recherche ANR-17-CE16-0017Agence Nationale de la Recherche ANR-21-ENM3-0003-04LABoratoires d'EXcellence ARCANE ANR-10-LABX-65LHW-Stiftung LHW-Stiftung
6 · The paper itself

Abstract

Usher syndrome (USH) is the most common cause of deaf-blindness in humans, with a prevalence of about 1/10,000 (~ 400,000 people worldwide). Cochlear implants are currently used to reduce the burden of hearing loss in severe-to-profoundly deaf patients, but many promising treatments including gene, cell, and drug therapies to restore the native function of the inner ear and retinal sensory cells are under investigation. The traditional clinical classification of Usher syndrome defines three major subtypes-USH1, 2 and 3-according to hearing loss severity and onset, the presence or absence of vestibular dysfunction, and age at onset of retinitis pigmentosa. Pathogenic variants of nine USH genes have been initially reported: MYO7A, USH1C, PCDH15, CDH23, and USH1G for USH1, USH2A, ADGRV1, and WHRN for USH2, and CLRN1 for USH3. Based on the co-occurrence of hearing and vision deficits, the list of USH genes has been extended to few other genes, but with limited supporting information. A consensus on combined criteria for Usher syndrome is crucial for the development of accurate diagnosis and to improve patient management. In recent years, a wealth of information has been obtained concerning the properties of the Usher proteins, related molecular networks, potential genotype-phenotype correlations, and the pathogenic mechanisms underlying the impairment or loss of hearing, balance and vision. The advent of precision medicine calls for a clear and more precise diagnosis of Usher syndrome, exploiting all the existing data to develop a combined clinical/genetic/network/functional classification for Usher syndrome.

Indexed as

Usher SyndromesGenetic Association StudiesHumansMutation

Identifiers

PMID35353227
PMCPMC9034986
OpenAlexW4220658202

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.